摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3α,4β,5α)-3-hydroxy-4-methoxyandrostan-17-one | 1516884-15-3

中文名称
——
中文别名
——
英文名称
(3α,4β,5α)-3-hydroxy-4-methoxyandrostan-17-one
英文别名
(3R,4R,5R,8R,9S,10R,13S,14S)-3-hydroxy-4-methoxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
(3α,4β,5α)-3-hydroxy-4-methoxyandrostan-17-one化学式
CAS
1516884-15-3
化学式
C20H32O3
mdl
——
分子量
320.472
InChiKey
QVUDHDZBCMSLHH-YBEMEBNRSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.58
  • 重原子数:
    23.0
  • 可旋转键数:
    1.0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.95
  • 拓扑面积:
    46.53
  • 氢给体数:
    1.0
  • 氢受体数:
    3.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (3α,4β,5α)-3-hydroxy-4-methoxyandrostan-17-one4-二甲氨基吡啶 、 sodium tetrahydroborate 、 cerium(III) chloride heptahydrate 、 三乙胺 、 potassium hydroxide 作用下, 以 乙醇二氯甲烷 为溶剂, 反应 23.0h, 生成 (3α,4β,17β)-4-methoxy-16-(phenylmethylene)-androstane-3,17-diol diacetate
    参考文献:
    名称:
    Neurosteroid Analogues. 18. Structure–Activity Studies of ent-Steroid Potentiators of γ-Aminobutyric Acid Type A Receptors and Comparison of Their Activities with Those of Alphaxalone and Allopregnanolone
    摘要:
    A model of the alignment of neurosteroids and ent-neurosteroids at the same binding site on gamma-aminobutyric acid type A (GABA(A)) receptors was evaluated for its ability to identify the structural features in ent-neurosteroids that enhance their activity as positive allosteric modulators of this receptor. Structural features that were identified included: (1) a ketone group at position C-16, (2) an axial 4 alpha-OMe group, and (3) a C-18 methyl group. Two ent-steroids were identified that were more potent than the anesthetic steroid alphaxalone in their threshold for and duration of loss of the righting reflex in mice. In tadpoles, loss of righting reflex for these two ent-steroids 0 occurs with EC50 values similar to those found for allopregnanolone. The results indicate that ent-steroids have considerable potential to be developed as anesthetic agents and as drugs to treat brain disorders that are ameliorated by positive allosteric modulators of GABA(A) receptor function.
    DOI:
    10.1021/jm401577c
  • 作为产物:
    描述:
    雄烯二酮甲酸硫酸双氧水溶剂黄146 作用下, 以 二氯甲烷 为溶剂, 反应 7.5h, 生成 (3α,4β,5α)-3-hydroxy-4-methoxyandrostan-17-one
    参考文献:
    名称:
    Neurosteroid Analogues. 18. Structure–Activity Studies of ent-Steroid Potentiators of γ-Aminobutyric Acid Type A Receptors and Comparison of Their Activities with Those of Alphaxalone and Allopregnanolone
    摘要:
    A model of the alignment of neurosteroids and ent-neurosteroids at the same binding site on gamma-aminobutyric acid type A (GABA(A)) receptors was evaluated for its ability to identify the structural features in ent-neurosteroids that enhance their activity as positive allosteric modulators of this receptor. Structural features that were identified included: (1) a ketone group at position C-16, (2) an axial 4 alpha-OMe group, and (3) a C-18 methyl group. Two ent-steroids were identified that were more potent than the anesthetic steroid alphaxalone in their threshold for and duration of loss of the righting reflex in mice. In tadpoles, loss of righting reflex for these two ent-steroids 0 occurs with EC50 values similar to those found for allopregnanolone. The results indicate that ent-steroids have considerable potential to be developed as anesthetic agents and as drugs to treat brain disorders that are ameliorated by positive allosteric modulators of GABA(A) receptor function.
    DOI:
    10.1021/jm401577c
点击查看最新优质反应信息

文献信息

  • Neuroactive steroids, compositions, and uses thereof
    申请人:Sage Therapeutics, Inc.
    公开号:US11046728B2
    公开(公告)日:2021-06-29
    Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    本文描述的是式 (I) 的神经活性类固醇: 或其药学上可接受的盐;其中 R1a 和 R1b 如本文所定义。在某些实施方案中,此类化合物被设想为 GABA 调节剂。本发明还提供了包含本发明化合物的药物组合物以及使用和治疗方法,例如用于诱导镇静和/或麻醉的方法。
  • [EN] NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF<br/>[FR] STÉROÏDES NEUROACTIFS, COMPOSITIONS, ET LEURS UTILISATIONS
    申请人:SAGE THERAPEUTICS INC
    公开号:WO2015010054A3
    公开(公告)日:2015-04-09
  • NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF
    申请人:Sage Therapeutics, Inc.
    公开号:EP3021852B1
    公开(公告)日:2021-01-27
  • Neurosteroid Analogues. 18. Structure–Activity Studies of <i>ent</i>-Steroid Potentiators of γ-Aminobutyric Acid Type A Receptors and Comparison of Their Activities with Those of Alphaxalone and Allopregnanolone
    作者:Mingxing Qian、Kathiresan Krishnan、Eva Kudova、Ping Li、Brad D. Manion、Amanda Taylor、George Elias、Gustav Akk、Alex S. Evers、Charles F. Zorumski、Steven Mennerick、Douglas F. Covey
    DOI:10.1021/jm401577c
    日期:2014.1.9
    A model of the alignment of neurosteroids and ent-neurosteroids at the same binding site on gamma-aminobutyric acid type A (GABA(A)) receptors was evaluated for its ability to identify the structural features in ent-neurosteroids that enhance their activity as positive allosteric modulators of this receptor. Structural features that were identified included: (1) a ketone group at position C-16, (2) an axial 4 alpha-OMe group, and (3) a C-18 methyl group. Two ent-steroids were identified that were more potent than the anesthetic steroid alphaxalone in their threshold for and duration of loss of the righting reflex in mice. In tadpoles, loss of righting reflex for these two ent-steroids 0 occurs with EC50 values similar to those found for allopregnanolone. The results indicate that ent-steroids have considerable potential to be developed as anesthetic agents and as drugs to treat brain disorders that are ameliorated by positive allosteric modulators of GABA(A) receptor function.
查看更多